ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGP vs SIBN // EV/EBITDA & P/E VALUATION

SpyGlass Pharma Inc. (NASDAQ) VS. SI-BONE Inc. (NASDAQ) • 15-METRIC TALLY: SGP 2 — SIBN 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGP VS. SIBN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGP SIBN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 79.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -10.30% -24.70 SIBN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -3.08% -0.90% -2.18 SIBN /fcf-yield <GO>
Operating Margin — -11.10% — TIE /operating-margins <GO>
Net Profit Margin — -9.40% — TIE /net-margins <GO>
Revenue Growth (YoY) — 20.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.73 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 6/9 -4.00 SIBN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 71.4 58.6 +12.74 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.09B $1.00B $83.0M SGP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGP REV SIBN REV SGP GROSS % SIBN GROSS % SGP FCF SIBN FCF
FY 2025 $0 $200.9M — 79.6% -$33.5M -$9.1M
FY 2024 $0 $167.2M — 79.0% -$24.0M -$22.9M
FY 2023 — $138.9M — — — -$18.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGP // BETA —
SIBN // BETA —